The reverse Warburg effect: Glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts

Cell Cycle

Volumn 9, Issue 10, 2010, Pages 1960-1971

  Bonuccelli, Gloria ^a   Whitaker Menezes, Diana ^a   Castello Cros, Remedios ^a   Pavlides, Stephanos ^a   Pestell, Richard G ^a   Fatatis, Alessandro ^b   Witkiewicz, Agnieszka K ^c   Vander Heiden, Matthew G ^d   Migneco, Gemma ^a   Chiavarina, Barbara ^a   Frank, Philippe G ^a   Capozza, Franco ^a   Flomenberg, Neal ^c   Martinez Outschoorn, Ubaldo E ^a,c   Sotgia, Federica ^a   Lisanti, Michael P ^a,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Aerobic glycolysis; Cancer associated fibroblast; Caveolin 1; Lactate dehydrogenase; M2 isoform of pyruvate kinase; Myofibroblast; Tumor stroma; Warburg effect

Indexed keywords

BIOLOGICAL MARKER; CAVEOLIN 1; GLYCOLYTIC ENZYME; TUMOR PROMOTER;

ANAEROBIC GLYCOLYSIS; ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; FIBROBLAST; METABOLITE; MOUSE; NONHUMAN; PARACRINE SIGNALING; PROTEOMICS; TUMOR GROWTH; TUMOR PROMOTION; TUMOR XENOGRAFT;

MUS MUSCULUS;

EID: 77953551959     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.10.11601     Document Type: Article

References (25)

1. Ronnov-Jessen L, Bissell MJ. Breast cancer by proxy: can the microenvironment be both the cause and consequence? Trends Mol Med 2009; 15:5-13.
2. Ghajar CM, Meier R, Bissell MJ. Quis custodiet ipsos custodies: who watches the watchmen? Am J Pathol 2009; 174:1996-9.
3. Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, Allen KG, et al. Human Breast Cancer-Associated Fibroblasts (CAFs) Show Caveolin-1 Downregulation and RB Tumor Suppressor Functional Inactivation: Implications for the Response to Hormonal Therapy. Cancer Biol Ther 2008; 7:1212-25.
4. Witkiewicz AK, Casimiro MC, Dasgupta A, Mercier I, Wang C, Bonuccelli G, et al. Towards a new "stromal-based" classification system for human breast cancer prognosis and therapy. Cell Cycle 2009; 8:1654-8.
5. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, et al. An Absence of Stromal Caveolin-1 Expression Predicts Early Tumor Recurrence and Poor Clinical Outcome in Human Breast Cancers. Am J Pathol 2009; 174:2023-34.
6. Sloan EK, Ciocca D, Pouliot N, Natoli A, Restall C, Henderson M, et al. Stromal Cell Expression of Caveolin-1 Predicts Outcome in Breast Cancer. Am J Pathol 2009; 174:2035-43.
7. Witkiewicz AK, Dasgupta A, Nguyen KH, Liu C, Kovatich AJ, Schwartz GF, et al. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther 2009; 8:1167-75.
8. Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, Lisanti MP. An Absence of Stromal Caveolin-1 is Associated with Advanced Prostate Cancer, Metastatic Disease and Epithelial Akt Activation. Cell Cycle 2009; 8:2420-4.
9. Williams TM, Sotgia F, Lee H, Hassan G, Di Vizio D, Bonuccelli G, et al. Stromal and Epithelial Caveolin-1 Both Confer a Protective Effect Against Mammary Hyperplasia and Tumorigenesis: Caveolin-1 Antagonizes Cyclin D1 Function in Mammary Epithelial Cells. Am J Pathol 2006; 169:1784-801. (Pubitemid 351182008)
10. -/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. Am J Pathol 2009; 174:746-61.
11. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009; 8:3984-4001.
12. King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989; 246:500-3. (Pubitemid 19273941)
13. Yi CH, Smith DJ, West WW, Hollingsworth MA. Loss of fibulin-2 expression is associated with breast cancer progression. Am J Pathol 2007; 170:1535-45.
14. Jung EJ, Moon HG, Cho BI, Jeong CY, Joo YT, Lee YJ, et al. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 2007; 120:2331-8.
15. van den Brule FA, Waltregny D, Castronovo V. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J Pathol 2001; 193:80-7. (Pubitemid 32051116)
16. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029-33.
17. Funasaka T, Hogan V, Raz A. Phosphoglucose isomerase/autocrine motility factor mediates epithelial and mesenchymal phenotype conversions in breast cancer. Cancer Res 2009; 69:5349-56.
18. Reich NC. STAT3 revs up the powerhouse. Sci Signal 2009; 2:61.
19. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009; 324:1713-6.
20. Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, Koeck T, et al. Function of mitochondrial Stat3 in cellular respiration. Science 2009; 323:793-7.
21. Dang CV. p32 (C1QBP) and Cancer Cell Metabolism: Is the Warburg Effect a lot of hot air? Mol Cell Biol 2010.
22. Fogal V, Richardson A, Karmali PP, Scheffler IE, Smith JW, Ruoslahti E. Mitochondrial p32 Protein is a Critical Regulator of Tumor Metabolism via Maintenance of Oxidative Phosphorylation. Mol Cell Biol 2010.
23. Williams TM, Lee H, Cheung MW, Cohen AW, Razani B, Iyengar P, et al. Combined loss of INK4a and caveolin-1 synergistically enhances cell proliferation and oncogene-induced tumorigenesis: Role of INK4a/CAV-1 in mammary epithelial cell hyperplasia. J Biol Chem 2004; 279:24745-56.
24. Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ, et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo: Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 2004; 279:51630-46.
25. Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 2005; 382:669-78.